Ceramide Analog LCL768 Kills Head and Neck Cancer by Starving Mitochondria of Fumarate

Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer in which levels of a bioactive lipid called C18-ceramide are consistently reduced compared to adjacent healthy tissue. Prior research established that low C18-ceramide correlates with poor prognosis and metastasis, suggesting that restoring ceramide signaling could be therapeutically useful. This paper, published in Cancer Research, investigates how a novel ceramide analog drug called LCL768 exploits this vulnerability to kill HNSCC cells through a specific, metabolically driven form of programmed mitochondrial death called lethal mitophagy.

The study used multiple HNSCC cell lines (UM-SCC-1A, UM-SCC-22A/B, UM-SCC-47A, MOC2, SCC27), 2D patient-derived organoids, and in vivo mouse tumor models. LCL768 was shown to induce CerS1-mediated endogenous C18-ceramide accumulation specifically within mitochondria. Unlike the previously characterized mechanism involving sodium selenite, this process did not require the p17/PERMIT transporter protein. Instead, LCL768-driven mitochondrial ceramide accumulation depended on nitric oxide synthase (iNOS)-mediated nitrosylation of DRP1 at cysteine residue C644. Cells expressing DRP1 mutants that could not bind ER or mitochondrial membranes (DRP1-MT and DRP1-ER mutants) failed to accumulate CerS1/C18-ceramide in mitochondria, blocked ER-mitochondrial membrane tethering via phosphatidylethanolamine-cardiolipin association, and abrogated LCL768-induced mitophagy, directly linking DRP1 structural function to ceramide-driven mitophagy.

A central and novel finding was the identification of fumarate depletion as a critical metabolic event downstream of LCL768-induced mitophagy. Untargeted metabolomics and isotope tracing with ¹³C3-pyruvate and ¹³C5-glutamine demonstrated that LCL768 significantly reduced intracellular fumarate levels. Fumarate was found to succinate PARKIN at its catalytic cysteine residue (Cys431), a post-translational modification that inhibits PARKIN's interaction with PINK1 and ubiquitin and thereby blocks mitophagy. When LCL768 depletes fumarate, PARKIN succination is attenuated, PARKIN becomes activated, and mitophagy is amplified in a feed-forward loop. Mutations at PARKIN-C431 (C431Q) phenocopied fumarate depletion by constitutively promoting PARKIN activation and mitophagy, validating the mechanistic model.

In vivo experiments using HNSCC mouse tumor models demonstrated robust tumor suppression by LCL768. Critically, exogenous fumarate supplementation reversed LCL768-mediated tumor suppression in mice, restored PARKIN succination, and prevented CerS1 mitochondrial trafficking and ER-mitochondrial tethering, providing strong in vivo validation that fumarate depletion is not a secondary effect but a required mechanistic step. The mt-mKeima mitophagy reporter assay confirmed that LCL768 induced significantly greater mitophagy flux than vehicle controls, and this was abolished by Drp1 or PARKIN knockdown.

This work establishes a complete mechanistic chain: LCL768 → iNOS/DRP1 nitrosylation → ER-mitochondria tethering → CerS1/C18-ceramide mitochondrial accumulation → mitophagy → fumarate depletion → reduced PARKIN succination → amplified PARKIN/PINK1 activation → lethal mitophagy → tumor suppression. The identification of fumarate as a metabolic rheostat for PARKIN activity represents a previously unknown regulatory mechanism with broad implications for cancer metabolism and potentially for neurodegenerative diseases where PARKIN dysfunction is central.